Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Accumulated Expenses (2022 - 2025)

Corvus Pharmaceuticals has reported Other Accumulated Expenses over the past 4 years, most recently at $566000.0 for Q3 2025.

  • Quarterly results put Other Accumulated Expenses at $566000.0 for Q3 2025, up 40.8% from a year ago — trailing twelve months through Sep 2025 was $566000.0 (up 40.8% YoY), and the annual figure for FY2024 was $289000.0, up 17.96%.
  • Other Accumulated Expenses for Q3 2025 was $566000.0 at Corvus Pharmaceuticals, up from $346000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for CRVS hit a ceiling of $566000.0 in Q3 2025 and a floor of $131000.0 in Q2 2022.
  • Median Other Accumulated Expenses over the past 4 years was $245000.0 (2023), compared with a mean of $266666.7.
  • Biggest five-year swings in Other Accumulated Expenses: soared 85.78% in 2023 and later crashed 52.77% in 2024.
  • Corvus Pharmaceuticals' Other Accumulated Expenses stood at $158000.0 in 2022, then soared by 55.06% to $245000.0 in 2023, then grew by 17.96% to $289000.0 in 2024, then soared by 95.85% to $566000.0 in 2025.
  • The last three reported values for Other Accumulated Expenses were $566000.0 (Q3 2025), $346000.0 (Q2 2025), and $296000.0 (Q1 2025) per Business Quant data.